ASTERIAS BIOTHERAPEUTICS, INC. AST Income Statement

Asterias biotherapeutics, inc. (AST)

Income statement / TTM

Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16	Dec'15	Sep'15	Jun'15	Mar'15	Dec'14	Sep'14	Jun'14	Mar'14	Dec'13	Sep'13	Jun'13	Mar'13	Dec'12
us-gaap_GrantMember
License Revenue [Member]
Royalties from Product Sales [Member]
REVENUE
Total revenue
0	0	-	-	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Grant income
-	-	1,817	-	-	-	6,979	6,572	5,466	4,678	3,817	3,007	3,441	2,371	1,712	1,035	0	0	0	-	-	-	-	0
Sale of cell lines
-	-	-	-	-	-	-	-	-	-	-	-	0	0	-	-	0	0	-	-	-	-	-	-
License revenue
-	-	0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Royalties from product sales
-	-	327	-	-	-	266	257	344	479	540	535	549	281	229	189	0	0	0	-	-	-	-	0
Total revenues
-	-	2,510	-	-	-	7,370	6,954	5,810	5,157	4,397	3,582	4,030	2,692	1,941	1,224	167	82	61	0	0	0	0	0
Cost of sales
190	214	175	165	162	140	128	128	121	238	270	268	277	143	146	95	83	41	0	-	0	0	-	0
Gross profit
541	2,089	2,335	3,877	5,604	6,014	7,242	6,826	5,689	4,919	4,127	3,314	3,753	2,549	1,795	1,129	84	41	0	-	0	0	-	0
EXPENSES
Research and development
17,187	20,301	23,668	26,640	28,079	26,687	25,722	25,467	22,997	22,394	20,071	17,321	17,317	15,256	14,303	13,310	10,296	8,877	6,724	4,319	1,932	0	0	0
Acquired in-process research and development
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	17,459	0	0	0	0
General and administrative
7,938	8,074	7,934	10,488	10,760	12,924	13,658	15,482	15,911	13,255	12,519	7,901	6,242	6,157	5,857	5,280	5,101	5,156	4,355	3,883	3,648	0	0	0
Total operating expenses
25,125	28,375	31,602	37,128	38,839	39,611	39,380	40,949	38,908	35,649	32,590	25,222	23,560	21,414	20,161	18,590	32,857	31,492	28,539	25,661	5,581	0	0	0
Loss from operations
-24,584	-26,286	-29,267	-33,251	-33,235	-33,597	-32,138	-34,123	-33,219	-30,730	-28,463	-21,908	-19,807	-18,865	-18,366	-17,461	-32,772	-31,450	-28,477	-25,661	-5,581	0	0	0
OTHER INCOME/(EXPENSE)
Gain from change in fair value on warrant liability
4,558	4,895	4,473	5,908	2,663	-1,838	-154	-3,108	-2,367	1,628	0	-	0	0	-	-	-	-	-	-	-	-	-	-
Gain from change in fair value of marketable equity securities
0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Loss from change in fair value of marketable equity securities
-	0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Gain from change in fair value of marketable equity securities
-	0	0	-	-	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Interest expense, net
-403	-427	-446	-465	-483	-499	-524	-546	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-
Interest expense, net
-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-	-12	-11	-6	-2	0	0	0	0
Other expense, net
-437	-573	-592	-564	0	0	0	-	0	0	-	-	0	0	-	-2	0	0	0	-	-	-	-	-
Other income/(expense), net
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1	0	0	0
Gain on sale of fixed assets
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2	0	0	0
Total other income/(expense), net
4,288	3,635	4,870	4,879	1,996	-2,383	-724	-3,691	-2,951	1,042	-474	-347	-203	-72	-27	-12	-16	-11	-4	0	3	0	0	0
LOSS BEFORE INCOME TAX BENEFIT
-	-	-	-	-	-	-	-37,814	-36,170	-29,688	-28,937	-22,255	-20,011	-18,938	-18,394	-17,473	-32,788	-31,462	-28,481	-25,661	-5,577	0	0	0
Deferred income tax benefit
-	-	-	-	-	-	-	-2,325	-5,121	-5,780	-6,570	-7,252	-6,586	-7,338	-7,610	-7,376	-8,456	-6,143	-4,630	-3,281	0	0	0	0
NET LOSS
-20,296	-22,651	-24,397	-28,372	-31,169	-35,008	-31,439	-35,489	-31,049	-23,908	-22,367	-15,003	-13,424	-11,599	-10,783	-10,097	-24,332	-25,319	-23,851	-22,380	-5,577	0	0	0
Unrealized gain (loss) on available-for-sale securities, net
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-
COMPREHENSIVE LOSS
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-
BASIC AND DILUTED NET LOSS PER SHARE (in dollars per share)
-0.08	-0.13	-0.04	-0.11	-0.14	-0.18	-0.13	-0.20	-0.24	-0.12	-0.27	-0.14	-0.09	-0.10	-0.09	-0.12	-0.05	-0.09	-0.07	90.30	-51.62	-25.81	-15.77	-14.69
WEIGHTED AVERAGE SHARES OUTSTANDING: BASIC AND DILUTED (in shares)
55,531	55,138	54,185	54,445	49,771	48,511	48,357	46,462	45,193	41,777	38,304	37,910	37,602	34,590	31,670	30,906	30,899	30,576	30,498	30,748	51	51	51	51